TCR Therapy- Pipeline Insight, 2025
Description
DelveInsight’s, “TCR Therapy- Pipeline Insight, 2025” report provides comprehensive insights about 80+ companies and 100+ pipeline drugs in TCR Therapy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
TCR Therapy: Overview
The T-cell receptor (TCR) is a molecule found on the surface of T cells, or T lymphocytes, that is responsible for recognizing fragments of antigen as peptides bound to major histocompatibility complex (MHC) molecules. The binding between TCR and antigen peptides is of relatively low affinity and is degenerate, that is, many TCRs recognize the same antigen peptide and many antigen peptides are recognized by the same TCR.
The TCR is a disulfide-linked membrane-anchored heterodimeric protein normally consisting of the highly variable alpha (α) and beta (β) chains expressed as part of a complex with the invariant CD3 chain molecules. T cells expressing this receptor are referred to as α:β (or αβ) T cells, though a minority of T cells express an alternate receptor, formed by variable gamma (γ) and delta (δ) chains, referred as γδ T cells. Each chain is composed of two extracellular domains: Variable (V) region and a Constant (C) region, both of Immunoglobulin superfamily (IgSF) domain forming antiparallel β-sheets. The Constant region is proximal to the cell membrane, followed by a transmembrane region and a short cytoplasmic tail, while the Variable region binds to the peptide/MHC complex.
Successfully rearranged TCRs are expressed at the T cell surface and audition for selection on thymic self-pMHC ligands. The net result of thymic selection is that the post-selection repertoire is largely purged of most clonotypes. Typically, only one in a hundred thymocytes are thought to be granted access to the periphery. Assessing the relative distribution of TCR clonotypes has long been a challenge in the naive pool because of low precursor frequency. Nevertheless, identifying the factors that shape the composition of the naive repertoire is critical to understanding of protective T cell-mediated immunity because naive lymphocytes represent the precursor pool from which all immune responses arise.
Improving the function of TCR-engineered T cells is critical to overcome inhibitory factors within the tumor microenvironment and elicit tumor regression. Many efforts to enhance antigen reactivity and circumvent T cell tolerance have focused on increasing TCR signal strength and generating highly functional T cells. Immune checkpoint proteins, such as PD-1 and CTLA-4, can prevent the activation of T cells in immune system. A recent study demonstrating the benefits of this approach created CD8+ T cells expressing two additional receptors; a gp100 antigen-specific TCR and a melanoma-associated chondroitin sulfate proteoglycan specific CAR. These T cells using combined recognition pathways showed greater efficacy by by-passing the mechanisms by which tumor cells escape immune recognition. In conclusion, TCR-engineered T cells therapy, in combination with drugs targeting chemokines, cytokines, and immune checkpoint proteins, may obtain better clinical responses in future treatments.
""TCR Therapy- Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the TCR Therapy pipeline landscape is provided which includes the disease overview and TCR Therapy treatment guidelines. The assessment part of the report embraces, in depth TCR Therapy commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, TCR Therapy collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the TCR Therapy report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, II/III I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
TCR Therapy Emerging Drugs
Further product details are provided in the report……..
TCR Therapy: Therapeutic Assessment
This segment of the report provides insights about the different TCR Therapy drugs segregated based on following parameters that define the scope of the report, such as:
TCR Therapy: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses TCR Therapy therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging TCR Therapy drugs.
TCR Therapy Report Insights
Current Treatment Scenario and Emerging Therapies:
Please Note: It will take 3-4 business days to complete the report upon order confirmation.
Geography Covered
- Global coverage
TCR Therapy: Overview
The T-cell receptor (TCR) is a molecule found on the surface of T cells, or T lymphocytes, that is responsible for recognizing fragments of antigen as peptides bound to major histocompatibility complex (MHC) molecules. The binding between TCR and antigen peptides is of relatively low affinity and is degenerate, that is, many TCRs recognize the same antigen peptide and many antigen peptides are recognized by the same TCR.
The TCR is a disulfide-linked membrane-anchored heterodimeric protein normally consisting of the highly variable alpha (α) and beta (β) chains expressed as part of a complex with the invariant CD3 chain molecules. T cells expressing this receptor are referred to as α:β (or αβ) T cells, though a minority of T cells express an alternate receptor, formed by variable gamma (γ) and delta (δ) chains, referred as γδ T cells. Each chain is composed of two extracellular domains: Variable (V) region and a Constant (C) region, both of Immunoglobulin superfamily (IgSF) domain forming antiparallel β-sheets. The Constant region is proximal to the cell membrane, followed by a transmembrane region and a short cytoplasmic tail, while the Variable region binds to the peptide/MHC complex.
Successfully rearranged TCRs are expressed at the T cell surface and audition for selection on thymic self-pMHC ligands. The net result of thymic selection is that the post-selection repertoire is largely purged of most clonotypes. Typically, only one in a hundred thymocytes are thought to be granted access to the periphery. Assessing the relative distribution of TCR clonotypes has long been a challenge in the naive pool because of low precursor frequency. Nevertheless, identifying the factors that shape the composition of the naive repertoire is critical to understanding of protective T cell-mediated immunity because naive lymphocytes represent the precursor pool from which all immune responses arise.
Improving the function of TCR-engineered T cells is critical to overcome inhibitory factors within the tumor microenvironment and elicit tumor regression. Many efforts to enhance antigen reactivity and circumvent T cell tolerance have focused on increasing TCR signal strength and generating highly functional T cells. Immune checkpoint proteins, such as PD-1 and CTLA-4, can prevent the activation of T cells in immune system. A recent study demonstrating the benefits of this approach created CD8+ T cells expressing two additional receptors; a gp100 antigen-specific TCR and a melanoma-associated chondroitin sulfate proteoglycan specific CAR. These T cells using combined recognition pathways showed greater efficacy by by-passing the mechanisms by which tumor cells escape immune recognition. In conclusion, TCR-engineered T cells therapy, in combination with drugs targeting chemokines, cytokines, and immune checkpoint proteins, may obtain better clinical responses in future treatments.
""TCR Therapy- Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the TCR Therapy pipeline landscape is provided which includes the disease overview and TCR Therapy treatment guidelines. The assessment part of the report embraces, in depth TCR Therapy commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, TCR Therapy collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence TCR Therapy R&D. The therapies under development are focused on novel approaches to treat/improve TCR Therapy.
This segment of the TCR Therapy report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, II/III I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
TCR Therapy Emerging Drugs
- Brenetafusp: Immunocore
- TAEST 16001: Guangdong Xiangxue Precision Medical Technology Co., Ltd
- NT-175: Neogene Therapeutics
- TSC 101: TScan Therapeutics
- SCG 162: SCG Cell Therapy
Further product details are provided in the report……..
TCR Therapy: Therapeutic Assessment
This segment of the report provides insights about the different TCR Therapy drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in TCR Therapy
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Intravenous
- Subcutaneous
- Oral
- Intramuscular
- Molecule Type
- Monoclonal antibody
- Small molecule
- Peptide
- Product Type
TCR Therapy: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses TCR Therapy therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging TCR Therapy drugs.
TCR Therapy Report Insights
- TCR Therapy Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing TCR Therapy drugs?
- How many TCR Therapy drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of TCR Therapy?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the TCR Therapy therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for TCR Therapy and their status?
- What are the key designations that have been granted to the emerging drugs?
- Immunocore
- Guangdong Xiangxue Precision Medical Technology Co., Ltd
- Neogene Therapeutics
- TScan Therapeutics
- SCG Cell Therapy
- Triumvira
- JW Therapeutics
- Immatics
- China Immunotech
- T-Cure
- 2seventy bio
- Brenetafusp
- TAEST 16001
- NT-175
- TSC 101
- SCG 162
- TAC01 HER2
- ECT204
- TSC-100
- IMA201
- CMV TCR-T
- 820 TCR
- MAGE-A4 TCR program
Please Note: It will take 3-4 business days to complete the report upon order confirmation.
Table of Contents
280 Pages
- Introduction
- Executive Summary
- TCR Therapy: Overview
- Introduction
- Structural characteristics of the TCR
- TCR diversity in the pre-selection repertoire
- TCR diversity in the naive pool
- Improving the function of TCR-engineered t cells in tumor microenvironment
- T-cell receptor-engineered T cells for cancer treatment: current status and future directions
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- TCR Therapy– DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Comparative Analysis
- Brenetafusp: Immunocore
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Comparative Analysis
- TAEST 16001: Guangdong Xiangxue Precision Medical Technology Co., Ltd
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- Comparative Analysis
- NT-175: Neogene Therapeutics
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Comparative Analysis
- SCG 162: SCG Cell Therapy
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- Comparative Analysis
- TCR Therapy Key Companies
- TCR Therapy Key Products
- TCR Therapy- Unmet Needs
- TCR Therapy- Market Drivers and Barriers
- TCR Therapy- Future Perspectives and Conclusion
- TCR Therapy Analyst Views
- TCR Therapy Key Companies
- Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
